# Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis

> **NCT01615887** · PHASE2 · COMPLETED · sponsor: **State University of New York at Buffalo** · enrollment: 63 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** lisdexamfetamine sulfate
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01615887
- **Lead sponsor:** State University of New York at Buffalo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2022-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01615887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01615887, "Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01615887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*